Janssen Research & Development, formerly known as Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), provides research and development support for the pharmaceutical business units of parent company Johnson & Johnson. The company divides its main research processes into three franchises: central nervous system and internal medicine; biotech, immunology, and oncology (in concert with fellow J&J subsidiary Janssen Biotech); and virology (with another J&J unit, Tibotec). The subsidiary -- which represents the largest segment of J&J's pharmaceutical R&D -- also does research in collaboration with other pharmaceutical organizations and biotech researchers.
Many of the medicines researched and developed by Janssen Research & Development are now big global sellers for parent company J&J. Some of the top products are Topamax for epilepsy, antipsychotic Risperdal, Procrit for anemia, Stelara for psoriasis, Prezista for HIV, and Concerta for attention deficit hyperactivity disorder (ADHD).
Its current development pipeline, which it hopes will produce tomorrow's blockbusters, includes potential treatments for diabetes, leukemia, ovarian cancer, HIV, and stroke prevention. It has about two dozen drugs in late-stage clinical trials or awaiting FDA approval. Overall, J&J spends more than $4 billion on pharmaceutical research each year. Once the products are approved by regulators, they are passed along to other J&J units for commercialization.
Janssen Research & Development, has research hubs around the globe, including locations in China, France, India, Spain, Switzerland, the UK, and the US (California, New Jersey, and Pennsylvania). Its central nervous system and internal medicine unit works on psychiatric, neurology, pain, infection, cardiovascular, and metabolic disease targets, primarily at the La Jolla, California, research center. The unit launched Nucynta for pain in 2009, and it introduced Invega Sustenna, an injectable version of schizophrenia treatment Invega, in 2010. It also has late-stage cardiovascular (blood clotting) and neurological (Alzheimer's) treatments in development through collaborations with Bayer and Elan.
The company's biotech, immunology, and oncology organization primarily operates alongside Janssen Biotech (formerly named Centocor Ortho Biotech), which is based at facilities in Pennsylvania. After expanding its research organization through the purchase of California-based Cougar Biotechnology (2009), Janssen Biotech and Janssen Research & Development worked together to receive approval for Cougar's prostate cancer drug, Zytiga, in 2011.
Its virology division works with Tibotech on HIV and tuberculosis treatments from facilities in Belgium, Ireland, and the US. This division also has a partnership with with Vertex Pharmaceuticals on a potential drug for hepatitis C.